Publications Molecular Biology of Sarcomas

Publications from OUS - Molecular Biology of Sarcomas (Wesche)

245 publications found

Publications 2024

1. Heinrich MC, Jones RL, George S, Gelderblom H, Schöffski P, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Reichmann W, Sprott K, Achour H et al. (2024)
   Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial
   Nat Med, 30 (2), 498-506
   DOI 10.1038/s41591-023-02734-5, PubMed 38182785
2. Zhou Y, Ray PS, Zhu J, Stein F, Rettel M, Sekaran T, Sahadevan S, Perez-Perri JI, Roth EK, Myklebost O, Meza-Zepeda LA, von Deimling A, Fu C, Brosig AN, Boye K, Nathrath M, Blattmann C, Lehner B, Hentze MW, Kulozik AE (2024)
   Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma
   Nat Commun, 15 (1), 2810
   DOI 10.1038/s41467-024-47031-y, PubMed 38561347

Publications 2023

1. Anzar I, Malone B, Samarakoon P, Vardaxis I, Simovski B, Fontenelle H, Meza-Zepeda LA, Stratford R, Keung EZ, Burgess M, Tawbi HA, Myklebost O, Clancy T (2023)
   The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition
   Front Immunol, 14, 1226445
   DOI 10.3389/fimmu.2023.1226445, PubMed 37799721
2. Ballinger ML, Pattnaik S, Mundra PA, Zaheed M, Rath E, Priestley P, Baber J, Ray-Coquard I, Isambert N, Causeret S, van der Graaf WTA, Puri A, Duffaud F, Le Cesne A, Seddon B, Chandrasekar C, Schiffman JD, Brohl AS, James PA, Kurtz JE, Penel N, Myklebost O, Meza-Zepeda LA, Pickett H, Kansara M et al. (2023)
   Heritable defects in telomere and mitotic function selectively predispose to sarcomas
   Science, 379 (6629), 253-260
   DOI 10.1126/science.abj4784, PubMed 36656928
3. Holme B, Bjørnerud B, Pedersen NM, de la Ballina LR, Wesche J, Haugsten EM (2023)
   Automated tracking of cell migration in phase contrast images with CellTraxx
   Sci Rep, 13 (1), 22982
   DOI 10.1038/s41598-023-50227-9, PubMed 38151514
4. Nakken S, Gundersen S, Bernal FLM, Polychronopoulos D, Hovig E, Wesche J (2023)
   Comprehensive interrogation of gene lists from genome-scale cancer screens with oncoEnrichR
   Int J Cancer, 153 (10), 1819-1828
   DOI 10.1002/ijc.34666, PubMed 37551617
5. Namløs HM, Khelik K, Nakken S, Vodák D, Hovig E, Myklebost O, Boye K, Meza-Zepeda LA (2023)
   Chromosomal instability and a deregulated cell cycle are intrinsic features of high-risk gastrointestinal stromal tumours with a metastatic potential
   Mol Oncol, 17 (11), 2432-2450
   DOI 10.1002/1878-0261.13514, PubMed 37622176

Publications 2022

1. Fiorito E, Szybowska P, Haugsten EM, Kostas M, Øy GF, Wiedlocha A, Singh S, Nakken S, Mælandsmo GM, Fletcher JA, Meza-Zepeda LA, Wesche J (2022)
   Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma
   Br J Cancer, 127 (11), 1939-1953
   DOI 10.1038/s41416-022-01973-6, PubMed 36097178
2. Georgiesh T, Aggerholm-Pedersen N, Schöffski P, Zhang Y, Napolitano A, Bovée JVMG, Hjelle Å, Tang G, Spalek M, Nannini M, Swanson D, Baad-Hansen T, Sciot R, Hesla AC, Huang P, Dorleijn D, Haugland HK, Lacambra M, Skoczylas J, Pantaleo MA, Haas RL, Meza-Zepeda LA, Haller F, Czarnecka AM, Loong H et al. (2022)
   Validation of a novel risk score to predict early and late recurrence in solitary fibrous tumour
   Br J Cancer, 127 (10), 1793-1798
   DOI 10.1038/s41416-022-01959-4, PubMed 36030294
3. Giliberto M, Santana LM, Holien T, Misund K, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA, Coward E, Waage A, Taskén K, Skånland SS (2022)
   Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines
   Front Oncol, 12, 1040730
   DOI 10.3389/fonc.2022.1040730, PubMed 36523963
4. Gorunova L, Boye K, Panagopoulos I, Berner JM, Bjerkehagen B, Hompland I, Lobmaier I, Hølmebakk T, Hveem TS, Heim S, Micci F (2022)
   Cytogenetic and molecular analyses of 291 gastrointestinal stromal tumors: site-specific cytogenetic evolution as evidence of pathogenetic heterogeneity
   Oncotarget, 13, 508-517
   DOI 10.18632/oncotarget.28209, PubMed 35284037
5. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
   Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
   J Transl Med, 20 (1), 225
   DOI 10.1186/s12967-022-03432-5, PubMed 35568909
6. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
   Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
   J Transl Med, 20 (1), 317
   DOI 10.1186/s12967-022-03518-0, PubMed 35841045
7. Misund K, Hofste Op Bruinink D, Coward E, Hoogenboezem RM, Rustad EH, Sanders MA, Rye M, Sponaas AM, van der Holt B, Zweegman S, Hovig E, Meza-Zepeda LA, Sundan A, Myklebost O, Sonneveld P, Waage A (2022)
   Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence
   Leukemia, 36 (7), 1887-1897
   DOI 10.1038/s41375-022-01597-y, PubMed 35643867
8. Namløs HM, Skårn M, Ahmed D, Grad I, Andresen K, Kresse SH, Munthe E, Serra M, Scotlandi K, Llombart-Bosch A, Myklebost O, Lind GE, Meza-Zepeda LA (2022)
   miR-486-5p expression is regulated by DNA methylation in osteosarcoma
   BMC Genomics, 23 (1), 142
   DOI 10.1186/s12864-022-08346-6, PubMed 35172717
9. Pinto R, Hauge T, Jeanmougin M, Pharo HD, Kresse SH, Honne H, Winge SB, Five MB, Kumar T, Mala T, Hauge T, Johnson E, Lind GE (2022)
   Targeted genetic and epigenetic profiling of esophageal adenocarcinomas and non-dysplastic Barrett's esophagus
   Clin Epigenetics, 14 (1), 77
   DOI 10.1186/s13148-022-01287-7, PubMed 35701814
10. Stacchiotti S, Dürr HR, Schaefer IM, Woertler K, Haas R, Trama A, Caraceni A, Bajpai J, Baldi GG, Bernthal N, Blay JY, Boye K, Broto JM, Chen WT, Dei Tos PA, Desai J, Emhofer S, Eriksson M, Gronchi A, Gelderblom H, Hardes J, Hartmann W, Healey J, Italiano A, Jones RL et al. (2022)
    Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts
    Cancer Treat Rev, 112, 102491
    DOI 10.1016/j.ctrv.2022.102491, PubMed 36502615
11. Søreng K, Pankiv S, Bergsmark C, Haugsten EM, Dahl AK, de la Ballina LR, Yamamoto A, Lystad AH, Simonsen A (2022)
    ALFY localizes to early endosomes and cellular protrusions to facilitate directional cell migration
    J Cell Sci, 135 (4)
    DOI 10.1242/jcs.259138, PubMed 35099014
12. Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES, CONNECT Public–Private Partnership Consortium, Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R, InPreD-Norway and National Molecular Tumor Board Consortium, IMPRESS-Norway Consortium, Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å (2022)
    A national precision cancer medicine implementation initiative for Norway
    Nat Med, 28 (5), 885-887
    DOI 10.1038/s41591-022-01777-4, PubMed 35513529
13. Venizelos A, Engebrethsen C, Deng W, Geisler J, Geisler S, Iversen GT, Aas T, Aase HS, Seyedzadeh M, Steinskog ES, Myklebost O, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA, Lønning PE, Knappskog S, Eikesdal HP (2022)
    Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
    Genome Med, 14 (1), 86
    DOI 10.1186/s13073-022-01090-2, PubMed 35948919

Publications 2021

1. Boye K, Longhi A, Guren T, Lorenz S, Næss S, Pierini M, Taksdal I, Lobmaier I, Cesari M, Paioli A, Løndalen AM, Setola E, Hompland I, Meza-Zepeda LA, Sundby Hall K, Palmerini E (2021)
   Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
   Cancer Immunol Immunother, 70 (9), 2617-2624
   DOI 10.1007/s00262-021-02876-w, PubMed 33580363
2. Georgiesh T, Namløs HM, Sharma N, Lorenz S, Myklebost O, Bjerkehagen B, Meza-Zepeda LA, Boye K (2021)
   Clinical and molecular implications of NAB2-STAT6 fusion variants in solitary fibrous tumour
   Pathology, 53 (6), 713-719
   DOI 10.1016/j.pathol.2020.11.010, PubMed 33745702
3. Grad I, Hanes R, Ayuda-Durán P, Kuijjer ML, Enserink JM, Meza-Zepeda LA, Myklebost O (2021)
   Discovery of novel candidates for anti-liposarcoma therapies by medium-scale high-throughput drug screening
   PLoS One, 16 (3), e0248140
   DOI 10.1371/journal.pone.0248140, PubMed 33690666
4. Hølmebakk T, Boye K (2021)
   ASO Author Reflections: How to Identify Patients at Genuinely High Risk of Recurrence from Localized Gastrointestinal Stromal Tumor of the Stomach?
   Ann Surg Oncol, 28 (11), 6846-6847
   DOI 10.1245/s10434-021-09608-5, PubMed 33687615
5. Hølmebakk T, Boye K (2021)
   Correction to: ASO Author Reflections: How to Identify Patients at Genuinely High Risk of Recurrence from Localized Gastrointestinal Stromal Tumor of the Stomach?
   Ann Surg Oncol, 28 (Suppl 3), 873
   DOI 10.1245/s10434-021-09939-3, PubMed 33829360
6. Hølmebakk T, Wiedswang AM, Meza-Zepeda LA, Hompland I, Lobmaier IVK, Berner JM, Stoldt S, Boye K (2021)
   Integrating Anatomical, Molecular and Clinical Risk Factors in Gastrointestinal Stromal Tumor of the Stomach
   Ann Surg Oncol, 28 (11), 6837-6845
   DOI 10.1245/s10434-021-09605-8, PubMed 33651216
7. Krzyscik MA, Zakrzewska M, Sørensen V, Øy GF, Brunheim S, Haugsten EM, Mælandsmo GM, Wiedlocha A, Otlewski J (2021)
   Fibroblast Growth Factor 2 Conjugated with Monomethyl Auristatin E Inhibits Tumor Growth in a Mouse Model
   Biomacromolecules, 22 (10), 4169-4180
   DOI 10.1021/acs.biomac.1c00662, PubMed 34542998
8. Mariathasan AB, Boye K, Dueland S, Flatmark K, Larsen SG (2021)
   Metastases in locally advanced rectal cancer undergoing curatively intended treatment
   Eur J Surg Oncol, 47 (9), 2377-2383
   DOI 10.1016/j.ejso.2021.04.023, PubMed 34049768
9. Munson MJ, Mathai BJ, Ng MYW, Trachsel-Moncho L, de la Ballina LR, Schultz SW, Aman Y, Lystad AH, Singh S, Singh S, Wesche J, Fang EF, Simonsen A (2021)
   GAK and PRKCD are positive regulators of PRKN-independent mitophagy
   Nat Commun, 12 (1), 6101
   DOI 10.1038/s41467-021-26331-7, PubMed 34671015
10. Nakken S, Saveliev V, Hofmann O, Møller P, Myklebost O, Hovig E (2021)
    Cancer Predisposition Sequencing Reporter (CPSR): A flexible variant report engine for high-throughput germline screening in cancer
    Int J Cancer, 149 (11), 1955-1960
    DOI 10.1002/ijc.33749, PubMed 34310709
11. Peneder P, Stütz AM, Surdez D, Krumbholz M, Semper S, Chicard M, Sheffield NC, Pierron G, Lapouble E, Tötzl M, Ergüner B, Barreca D, Rendeiro AF, Agaimy A, Boztug H, Engstler G, Dworzak M, Bernkopf M, Taschner-Mandl S, Ambros IM, Myklebost O, Marec-Bérard P, Burchill SA, Brennan B, Strauss SJ et al. (2021)
    Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden
    Nat Commun, 12 (1), 3230
    DOI 10.1038/s41467-021-23445-w, PubMed 34050156
12. Stabell M, Sæther T, Røhr ÅK, Gabrielsen OS, Myklebost O (2021)
    Methylation-dependent SUMOylation of the architectural transcription factor HMGA2
    Biochem Biophys Res Commun, 552, 91-97
    DOI 10.1016/j.bbrc.2021.02.099, PubMed 33744765
13. Sveen A, Johannessen B, Eilertsen IA, Røsok BI, Gulla M, Eide PW, Bruun J, Kryeziu K, Meza-Zepeda LA, Myklebost O, Bjørnbeth BA, Skotheim RI, Nesbakken A, Lothe RA (2021)
    The expressed mutational landscape of microsatellite stable colorectal cancers
    Genome Med, 13 (1), 142
    DOI 10.1186/s13073-021-00955-2, PubMed 34470667
14. Szybowska P, Kostas M, Wesche J, Haugsten EM, Wiedlocha A (2021)
    Negative Regulation of FGFR (Fibroblast Growth Factor Receptor) Signaling
    Cells, 10 (6)
    DOI 10.3390/cells10061342, PubMed 34071546
15. Vikan AK, Kostas M, Haugsten EM, Selbo PK, Wesche J (2021)
    Efficacy and Selectivity of FGF2-Saporin Cytosolically Delivered by PCI in Cells Overexpressing FGFR1
    Cells, 10 (6)
    DOI 10.3390/cells10061476, PubMed 34204611
16. Wiedlocha A, Haugsten EM, Zakrzewska M (2021)
    Roles of the FGF-FGFR Signaling System in Cancer Development and Inflammation
    Cells, 10 (9)
    DOI 10.3390/cells10092231, PubMed 34571880

Publications 2020

1. Dagenborg VJ, Marshall SE, Yaqub S, Grzyb K, Boye K, Lund-Iversen M, Høye E, Berstad AE, Fretland ÅA, Edwin B, Ree AH, Flatmark K (2020)
   Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases
   Cancer Biol Ther, 21 (5), 432-440
   DOI 10.1080/15384047.2020.1721252, PubMed 32098573
2. Fleten KG, Lund-Andersen C, Waagene S, Abrahamsen TW, Mørch Y, Boye K, Torgunrud A, Flatmark K (2020)
   Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models
   Transl Oncol, 13 (8), 100793
   DOI 10.1016/j.tranon.2020.100793, PubMed 32447231
3. Georgiesh T, Boye K, Bjerkehagen B (2020)
   A novel risk score to predict early and late recurrence in solitary fibrous tumour
   Histopathology, 77 (1), 123-132
   DOI 10.1111/his.14078, PubMed 31991494
4. Ree AH, Nygaard V, Boye K, Heinrich D, Dueland S, Bergheim IR, Johansen C, Beiske K, Negård A, Lund-Iversen M, Nygaard V, Hovig E, Nakken S, Nasser S, Julsrud L, Reisse CH, Ruud EA, Kristensen VN, Flørenes VA, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Russnes HG, Mælandsmo GM, Flatmark K (2020)
   Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
   Acta Oncol, 59 (7), 733-740
   DOI 10.1080/0284186X.2020.1742377, PubMed 32208873
5. Serguienko A, Braadland P, Meza-Zepeda LA, Bjerkehagen B, Myklebost O (2020)
   Accurate 3-gene-signature for early diagnosis of liposarcoma progression
   Clin Sarcoma Res, 10, 4
   DOI 10.1186/s13569-020-0126-1, PubMed 32158531
6. Tadele DS, Robertson J, Crispin R, Herrera MC, Chlubnová M, Piechaczyk L, Ayuda-Durán P, Singh SK, Gedde-Dahl T, Fløisand Y, Skavland J, Wesche J, Gjertsen BT, Enserink JM (2020)
   A cell competition-based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation
   J Biol Chem, 296, 100179
   DOI 10.1074/jbc.RA120.015285, PubMed 33303632
7. Wise JF, Nakken S, Steen CB, Vodák D, Trøen G, Johannessen B, Lingjærde OC, Hilden V, Blaker YN, Bai B, Aasheim LB, Pasanen A, Lorenz S, Sveen A, Lothe RA, Myklebost O, Leppä S, Meza-Zepeda LA, Beiske K, Lawrence MS, Hovig E, Myklebust JH, Smeland EB, Holte H (2020)
   Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
   Blood Adv, 4 (9), 1859-1866
   DOI 10.1182/bloodadvances.2019001325, PubMed 32374878

Publications 2019

1. Forthun RB, Hovland R, Schuster C, Puntervoll H, Brodal HP, Namløs HM, Aasheim LB, Meza-Zepeda LA, Gjertsen BT, Knappskog S, Straume O (2019)
   ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab
   Sci Rep, 9 (1), 17471
   DOI 10.1038/s41598-019-53917-5, PubMed 31767937
2. Goodridge JP, Jacobs B, Saetersmoen ML, Clement D, Hammer Q, Clancy T, Skarpen E, Brech A, Landskron J, Grimm C, Pfefferle A, Meza-Zepeda L, Lorenz S, Wiiger MT, Louch WE, Ask EH, Liu LL, Oei VYS, Kjällquist U, Linnarsson S, Patel S, Taskén K, Stenmark H, Malmberg KJ (2019)
   Remodeling of secretory lysosomes during education tunes functional potential in NK cells
   Nat Commun, 10 (1), 514
   DOI 10.1038/s41467-019-08384-x, PubMed 30705279
3. Hanes R, Munthe E, Grad I, Han J, Karlsen I, McCormack E, Meza-Zepeda LA, Stratford EW, Myklebost O (2019)
   Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma
   Cells, 8 (2)
   DOI 10.3390/cells8020189, PubMed 30795553
4. Hausott B, Förste A, Zach F, Mangger S, Haugsten EM, Klimaschewski L (2019)
   Endocytosis and Transport of Growth Factor Receptors in Peripheral Axon Regeneration: Novel Lessons from Neurons Expressing Lysine-Deficient FGF Receptor Type 1 in vitro
   Anat Rec (Hoboken), 302 (8), 1268-1275
   DOI 10.1002/ar.24120, PubMed 30950230
5. Namløs HM, Boye K, Meza-Zepeda LA (2019)
   Cell-free DNA in blood as a noninvasive insight into the sarcoma genome
   Mol Aspects Med, 72, 100827
   DOI 10.1016/j.mam.2019.10.004, PubMed 31703948
6. Pashov A, Shivarov V, Hadzhieva M, Kostov V, Ferdinandov D, Heintz KM, Pashova S, Todorova M, Vassilev T, Kieber-Emmons T, Meza-Zepeda LA, Hovig E (2019)
   Diagnostic Profiling of the Human Public IgM Repertoire With Scalable Mimotope Libraries
   Front Immunol, 10, 2796
   DOI 10.3389/fimmu.2019.02796, PubMed 31849974
7. Sneeggen M, Pedersen NM, Campsteijn C, Haugsten EM, Stenmark H, Schink KO (2019)
   WDFY2 restrains matrix metalloproteinase secretion and cell invasion by controlling VAMP3-dependent recycling
   Nat Commun, 10 (1), 2850
   DOI 10.1038/s41467-019-10794-w, PubMed 31253801
8. Szybowska P, Kostas M, Wesche J, Wiedlocha A, Haugsten EM (2019)
   Cancer Mutations in FGFR2 Prevent a Negative Feedback Loop Mediated by the ERK1/2 Pathway
   Cells, 8 (6)
   DOI 10.3390/cells8060518, PubMed 31146385
9. Zakrzewska M, Opalinski L, Haugsten EM, Otlewski J, Wiedlocha A (2019)
   Crosstalk between p38 and Erk 1/2 in Downregulation of FGF1-Induced Signaling
   Int J Mol Sci, 20 (8)
   DOI 10.3390/ijms20081826, PubMed 31013829

Publications 2018

1. Birkeland E, Zhang S, Poduval D, Geisler J, Nakken S, Vodak D, Meza-Zepeda LA, Hovig E, Myklebost O, Knappskog S, Lønning PE (2018)
   Patterns of genomic evolution in advanced melanoma
   Nat Commun, 9 (1), 2665
   DOI 10.1038/s41467-018-05063-1, PubMed 29991680
2. Fafilek B, Balek L, Bosakova MK, Varecha M, Nita A, Gregor T, Gudernova I, Krenova J, Ghosh S, Piskacek M, Jonatova L, Cernohorsky NH, Zieba JT, Kostas M, Haugsten EM, Wesche J, Erneux C, Trantirek L, Krakow D, Krejci P (2018)
   The inositol phosphatase SHIP2 enables sustained ERK activation downstream of FGF receptors by recruiting Src kinases
   Sci Signal, 11 (548)
   DOI 10.1126/scisignal.aap8608, PubMed 30228226
3. Gouravan S, Meza-Zepeda LA, Myklebost O, Stratford EW, Munthe E (2018)
   Preclinical Evaluation of Vemurafenib as Therapy for BRAF^V600E Mutated Sarcomas
   Int J Mol Sci, 19 (4)
   DOI 10.3390/ijms19040969, PubMed 29570692
4. Kostas M, Haugsten EM, Zhen Y, Sørensen V, Szybowska P, Fiorito E, Lorenz S, Jones N, de Souza GA, Wiedlocha A, Wesche J (2018)
   Protein Tyrosine Phosphatase Receptor Type G (PTPRG) Controls Fibroblast Growth Factor Receptor (FGFR) 1 Activity and Influences Sensitivity to FGFR Kinase Inhibitors
   Mol Cell Proteomics, 17 (5), 850-870
   DOI 10.1074/mcp.RA117.000538, PubMed 29371290
5. Kresse SH, Namløs HM, Lorenz S, Berner JM, Myklebost O, Bjerkehagen B, Meza-Zepeda LA (2018)
   Evaluation of commercial DNA and RNA extraction methods for high-throughput sequencing of FFPE samples
   PLoS One, 13 (5), e0197456
   DOI 10.1371/journal.pone.0197456, PubMed 29771965
6. Løvf M, Zhao S, Axcrona U, Johannessen B, Bakken AC, Carm KT, Hoff AM, Myklebost O, Meza-Zepeda LA, Lie AK, Axcrona K, Lothe RA, Skotheim RI (2018)
   Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity
   Eur Urol, 75 (3), 498-505
   DOI 10.1016/j.eururo.2018.08.009, PubMed 30181068
7. Namløs HM, Boye K, Mishkin SJ, Barøy T, Lorenz S, Bjerkehagen B, Stratford EW, Munthe E, Kudlow BA, Myklebost O, Meza-Zepeda LA (2018)
   Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor
   Mol Cancer Ther, 17 (11), 2473-2480
   DOI 10.1158/1535-7163.MCT-18-0174, PubMed 30097488
8. Vodák D, Lorenz S, Nakken S, Aasheim LB, Holte H, Bai B, Myklebost O, Meza-Zepeda LA, Hovig E (2018)
   Sample-Index Misassignment Impacts Tumour Exome Sequencing
   Sci Rep, 8 (1), 5307
   DOI 10.1038/s41598-018-23563-4, PubMed 29593270
9. Zhen Y, Haugsten EM, Singh SK, Wesche J (2018)
   Proximity Labeling by a Recombinant APEX2-FGF1 Fusion Protein Reveals Interaction of FGF1 with the Proteoglycans CD44 and CSPG4
   Biochemistry, 57 (26), 3807-3816
   DOI 10.1021/acs.biochem.8b00120, PubMed 29812912

Publications 2017

1. Behjati S, Tarpey PS, Haase K, Ye H, Young MD, Alexandrov LB, Farndon SJ, Collord G, Wedge DC, Martincorena I, Cooke SL, Davies H, Mifsud W, Lidgren M, Martin S, Latimer C, Maddison M, Butler AP, Teague JW, Pillay N, Shlien A, McDermott U, Futreal PA, Baumhoer D, Zaikova O et al. (2017)
   Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma
   Nat Commun, 8, 15936
   DOI 10.1038/ncomms15936, PubMed 28643781
2. Berg KCG, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA, Eknæs M, Lind GE, Myklebost O, Skotheim RI, Sveen A, Lothe RA (2017)
   Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies
   Mol Cancer, 16 (1), 116
   DOI 10.1186/s12943-017-0691-y, PubMed 28683746
3. Egeland EV, Boye K, Park D, Synnestvedt M, Sauer T, Oslo Breast Cancer Consortium (OSBREAC), Naume B, Borgen E, Mælandsmo GM (2017)
   Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer
   Breast Cancer Res Treat, 162 (1), 127-137
   DOI 10.1007/s10549-016-4096-1, PubMed 28058579
4. Engkvist ME, Stratford EW, Lorenz S, Meza-Zepeda LA, Myklebost O, Munthe E (2017)
   Analysis of the miR-34 family functions in breast cancer reveals annotation error of miR-34b
   Sci Rep, 7 (1), 9655
   DOI 10.1038/s41598-017-10189-1, PubMed 28848235
5. Helland Å, Brustugun OT, Nakken S, Halvorsen AR, Dønnem T, Bremnes R, Busund LT, Sun J, Lorenz S, Solberg SK, Jørgensen LH, Vodak D, Myklebost O, Hovig E, Meza-Zepeda LA (2017)
   High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival
   Int J Cancer, 141 (1), 184-190
   DOI 10.1002/ijc.30726, PubMed 28387924
6. Hompland I, Bruland ØS, Hølmebakk T, Poulsen JP, Stoldt S, Hall KS, Boye K (2017)
   Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort
   Acta Oncol, 56 (10), 1317-1323
   DOI 10.1080/0284186X.2017.1330555, PubMed 28557540
7. Namløs HM, Zaikova O, Bjerkehagen B, Vodák D, Hovig E, Myklebost O, Boye K, Meza-Zepeda LA (2017)
   Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report
   BMC Cancer, 17 (1), 29
   DOI 10.1186/s12885-016-2992-8, PubMed 28061772
8. Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA et al. (2017)
   Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
   ESMO Open, 2 (2), e000158
   DOI 10.1136/esmoopen-2017-000158, PubMed 28761742
9. Rustad EH, Coward E, Skytøen ER, Misund K, Holien T, Standal T, Børset M, Beisvag V, Myklebost O, Meza-Zepeda LA, Dai HY, Sundan A, Waage A (2017)
   Monitoring multiple myeloma by quantification of recurrent mutations in serum
   Haematologica, 102 (7), 1266-1272
   DOI 10.3324/haematol.2016.160564, PubMed 28385781
10. Serguienko A, Hanes R, Grad I, Wang MY, Myklebost O, Munthe E (2017)
    PP2A Regulatory Subunit B55γ is a Gatekeeper of Osteoblast Maturation and Lineage Maintenance
    Stem Cells Dev, 26 (19), 1375-1383
    DOI 10.1089/scd.2017.0129, PubMed 28805158
11. Sveen A, Johannessen B, Tengs T, Danielsen SA, Eilertsen IA, Lind GE, Berg KCG, Leithe E, Meza-Zepeda LA, Domingo E, Myklebost O, Kerr D, Tomlinson I, Nesbakken A, Skotheim RI, Lothe RA (2017)
    Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1
    Genome Med, 9 (1), 46
    DOI 10.1186/s13073-017-0434-0, PubMed 28539123

Publications 2016

1. Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, Puri A, Schiffman JD, Dite GS, Cipponi A, Maki RG, Brohl AS, Myklebost O, Stratford EW, Lorenz S, Ahn SM, Ahn JH, Kim JE, Shanley S, Beshay V, Randall RL, Judson I, Seddon B, Campbell IG, Young MA et al. (2016)
   Monogenic and polygenic determinants of sarcoma risk: an international genetic study
   Lancet Oncol, 17 (9), 1261-71
   DOI 10.1016/S1470-2045(16)30147-4, PubMed 27498913
2. Barøy T, Chilamakuri CS, Lorenz S, Sun J, Bruland ØS, Myklebost O, Meza-Zepeda LA (2016)
   Genome Analysis of Osteosarcoma Progression Samples Identifies FGFR1 Overexpression as a Potential Treatment Target and CHM as a Candidate Tumor Suppressor Gene
   PLoS One, 11 (9), e0163859
   DOI 10.1371/journal.pone.0163859, PubMed 27685995
3. Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA, Vodak D, Vu P, Sagerup C, Hovig E, Myklebost O, Børresen-Dale AL, Brustugun OT, Helland Å (2016)
   TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
   Front Genet, 7, 85
   DOI 10.3389/fgene.2016.00085, PubMed 27242894
4. Hanes R, Grad I, Lorenz S, Stratford EW, Munthe E, Reddy CC, Meza-Zepeda LA, Myklebost O (2016)
   Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma
   Oncotarget, 7 (34), 54583-54595
   DOI 10.18632/oncotarget.10518, PubMed 27409346
5. Lorenz S, Barøy T, Sun J, Nome T, Vodák D, Bryne JC, Håkelien AM, Fernandez-Cuesta L, Möhlendick B, Rieder H, Szuhai K, Zaikova O, Ahlquist TC, Thomassen GO, Skotheim RI, Lothe RA, Tarpey PS, Campbell P, Flanagan A, Myklebost O, Meza-Zepeda LA (2016)
   Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations
   Oncotarget, 7 (5), 5273-88
   DOI 10.18632/oncotarget.6567, PubMed 26672768
6. Munthe E, Riss PJ, Saga TA, Haraldsen I, Grad I, Bogsrud TV, Bach-Gansmo T (2016)
   FDG-based quantitative comparison of glucose metabolism in vitro, exemplified by a head-to-head comparison between a triple-negative breast cancer cell line and a non-malignant foetal cell line
   Clin Physiol Funct Imaging, 38 (1), 34-37
   DOI 10.1111/cpf.12378, PubMed 27297457
7. Safavi S, Järnum S, Vannas C, Udhane S, Jonasson E, Tomic TT, Grundevik P, Fagman H, Hansson M, Kalender Z, Jauhiainen A, Dolatabadi S, Stratford EW, Myklebost O, Eriksson M, Stenman G, Schneider-Stock R, Ståhlberg A, Åman P (2016)
   HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo
   Oncotarget, 7 (1), 433-45
   DOI 10.18632/oncotarget.6336, PubMed 26595521
8. Sandhu V, Wedge DC, Bowitz Lothe IM, Labori KJ, Dentro SC, Buanes T, Skrede ML, Dalsgaard AM, Munthe E, Myklebost O, Lingjærde OC, Børresen-Dale AL, Ikdahl T, Van Loo P, Nord S, Kure EH (2016)
   The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma
   Cancer Res, 76 (17), 5092-102
   DOI 10.1158/0008-5472.CAN-16-0658, PubMed 27488532
9. Våtsveen TK, Børset M, Dikic A, Tian E, Micci F, Lid AH, Meza-Zepeda LA, Coward E, Waage A, Sundan A, Kuehl WM, Holien T (2016)
   VOLIN and KJON-Two novel hyperdiploid myeloma cell lines
   Genes Chromosomes Cancer, 55 (11), 890-901
   DOI 10.1002/gcc.22388, PubMed 27311012

Publications 2015

1. Chymkowitch P, Nguéa AP, Aanes H, Koehler CJ, Thiede B, Lorenz S, Meza-Zepeda LA, Klungland A, Enserink JM (2015)
   Sumoylation of Rap1 mediates the recruitment of TFIID to promote transcription of ribosomal protein genes
   Genome Res, 25 (6), 897-906
   DOI 10.1101/gr.185793.114, PubMed 25800674
2. Fernandez-Cuesta L, Sun R, Menon R, George J, Lorenz S, Meza-Zepeda LA, Peifer M, Plenker D, Heuckmann JM, Leenders F, Zander T, Dahmen I, Koker M, Schöttle J, Ullrich RT, Altmüller J, Becker C, Nürnberg P, Seidel H, Böhm D, Göke F, Ansén S, Russell PA, Wright GM, Wainer Z et al. (2015)
   Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data
   Genome Biol, 16 (1), 7
   DOI 10.1186/s13059-014-0558-0, PubMed 25650807
3. Ju YS, Tubio JM, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A, Gerstung M, ICGC Prostate Cancer Working Group, ICGC Bone Cancer Working Group, ICGC Breast Cancer Working Group, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Lee MT, van't Veer LJ et al. (2015)
   Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells
   Genome Res, 25 (6), 814-24
   DOI 10.1101/gr.190470.115, PubMed 25963125
4. Kanojia D, Nagata Y, Garg M, Lee DH, Sato A, Yoshida K, Sato Y, Sanada M, Mayakonda A, Bartenhagen C, Klein HU, Doan NB, Said JW, Mohith S, Gunasekar S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Myklebost O, Yang H, Dugas M, Meza-Zepeda LA, Silberman AW, Forscher C et al. (2015)
   Genomic landscape of liposarcoma
   Oncotarget, 6 (40), 42429-44
   DOI 10.18632/oncotarget.6464, PubMed 26643872
5. Myklebost O (2015)
   Personalized cancer therapy for soft tissue sarcomas: progress and pitfalls
   Per Med, 12 (6), 593-602
   DOI 10.2217/pme.15.20, PubMed 29750616
6. Naderi EH, Skah S, Ugland H, Myklebost O, Sandnes DL, Torgersen ML, Josefsen D, Ruud E, Naderi S, Blomhoff HK (2015)
   Bone marrow stroma-derived PGE2 protects BCP-ALL cells from DNA damage-induced p53 accumulation and cell death
   Mol Cancer, 14 (1), 14
   DOI 10.1186/s12943-014-0278-9, PubMed 25623255
7. Rustad EH, Dai HY, Hov H, Coward E, Beisvag V, Myklebost O, Hovig E, Nakken S, Vodák D, Meza-Zepeda LA, Sandvik AK, Wader KF, Misund K, Sundan A, Aarset H, Waage A (2015)
   BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis
   Blood Cancer J, 5 (3), e299
   DOI 10.1038/bcj.2015.24, PubMed 25794135
8. Serguienko A, Grad I, Wennerstrøm AB, Meza-Zepeda LA, Thiede B, Stratford EW, Myklebost O, Munthe E (2015)
   Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA
   Oncotarget, 6 (4), 2451-65
   DOI 10.18632/oncotarget.3235, PubMed 25669981

Publications 2014

1. Anninga JK, Cleton-Jansen AM, Hassan B, Amary MF, Baumhoer D, Blay JY, Brugieres L, Ferrari S, Jurgens H, Kempf-Bielack B, Kovar H, Myklebost O, Nathrath M, Picci P, Riegman P, Schilham MW, Soliman R, Stark DP, Strauss S, Sydes M, Tarpey P, Thomas D, Whelan J, Wilhelm M, Zamzam M et al. (2014)
   Workshop report on the 2nd Joint ENCCA/EuroSARC European bone sarcoma network meeting: integration of clinical trials with tumour biology
   Clin. Sarcoma Res., 4, 4
   DOI 10.1186/2045-3329-4-4
2. Barøy T, Kresse SH, Skårn M, Stabell M, Castro R, Lauvrak S, Llombart-Bosch A, Myklebost O, Meza-Zepeda LA (2014)
   Reexpression of LSAMP inhibits tumor growth in a preclinical osteosarcoma model
   Mol Cancer, 13, 93
   DOI 10.1186/1476-4598-13-93, PubMed 24885297
3. Chilamakuri CS, Lorenz S, Madoui MA, Vodák D, Sun J, Hovig E, Myklebost O, Meza-Zepeda LA (2014)
   Performance comparison of four exome capture systems for deep sequencing
   BMC Genomics, 15 (1), 449
   DOI 10.1186/1471-2164-15-449, PubMed 24912484
4. Garsed DW, Marshall OJ, Corbin VD, Hsu A, Di Stefano L, Schröder J, Li J, Feng ZP, Kim BW, Kowarsky M, Lansdell B, Brookwell R, Myklebost O, Meza-Zepeda L, Holloway AJ, Pedeutour F, Choo KH, Damore MA, Deans AJ, Papenfuss AT, Thomas DM (2014)
   The architecture and evolution of cancer neochromosomes
   Cancer Cell, 26 (5), 653-67
   DOI 10.1016/j.ccell.2014.09.010, PubMed 25517748
5. Håkelien AM, Bryne JC, Harstad KG, Lorenz S, Paulsen J, Sun J, Mikkelsen TS, Myklebost O, Meza-Zepeda LA (2014)
   The regulatory landscape of osteogenic differentiation
   Stem Cells, 32 (10), 2780-93
   DOI 10.1002/stem.1759, PubMed 24898411
6. Skårn M, Noordhuis P, Wang MY, Veuger M, Kresse SH, Egeland EV, Micci F, Namløs HM, Håkelien AM, Olafsrud SM, Lorenz S, Haraldsen G, Kvalheim G, Meza-Zepeda LA, Myklebost O (2014)
   Generation and characterization of an immortalized human mesenchymal stromal cell line
   Stem Cells Dev, 23 (19), 2377-89
   DOI 10.1089/scd.2013.0599, PubMed 24857590
7. Tubio JMC, Li Y, Ju YS, Martincorena I, Cooke SL, Tojo M, Gundem G, Pipinikas CP, Zamora J, Raine K, Menzies A, Roman-Garcia P, Fullam A, Gerstung M, Shlien A, Tarpey PS, Papaemmanuil E, Knappskog S, Van Loo P, Ramakrishna M, Davies HR, Marshall J, Wedge DC, Teague JW, Butler AP et al. (2014)
   Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes
   Science, 345 (6196), 1251343
   DOI 10.1126/science.1251343, PubMed 25082706
8. Wennerström AB, Lothe IM, Sandhu V, Kure EH, Myklebost O, Munthe E (2014)
   Generation and characterisation of novel pancreatic adenocarcinoma xenograft models and corresponding primary cell lines
   PLoS One, 9 (8), e103873
   DOI 10.1371/journal.pone.0103873, PubMed 25148029

Publications 2013

1. Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gundem G, Davies H, Nik-Zainal S, Martin S, McLaren S, Goodie V, Robinson B, Butler A, Teague JW, Halai D, Khatri B, Myklebost O, Baumhoer D, Jundt G, Hamoudi R, Tirabosco R, Amary MF et al. (2013)
   Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone
   Nat Genet, 45 (12), 1479-82
   DOI 10.1038/ng.2814, PubMed 24162739
2. Bianchini L, Birtwisle L, Saâda E, Bazin A, Long E, Roussel JF, Michiels JF, Forest F, Dani C, Myklebost O, Birtwisle-Peyrottes I, Pedeutour F (2013)
   Identification of PPAP2B as a novel recurrent translocation partner gene of HMGA2 in lipomas
   Genes Chromosomes Cancer, 52 (6), 580-90
   DOI 10.1002/gcc.22055, PubMed 23508853
3. Doorn J, Fernandes HA, Le BQ, van de Peppel J, van Leeuwen JP, De Vries MR, Aref Z, Quax PH, Myklebost O, Saris DB, van Blitterswijk CA, de Boer J (2013)
   A small molecule approach to engineering vascularized tissue
   Biomaterials, 34 (12), 3053-63
   DOI 10.1016/j.biomaterials.2012.12.037, PubMed 23369216
4. Haugsten EM, Oppelt A, Wesche J (2013)
   Phosphatidylinositol 5-phosphate is a second messenger important for cell migration
   Commun Integr Biol, 6 (5), e25446
   DOI 10.4161/cib.25446, PubMed 24265857
5. Herlofsen SR, Bryne JC, Høiby T, Wang L, Issner R, Zhang X, Coyne MJ, Boyle P, Gu H, Meza-Zepeda LA, Collas P, Mikkelsen TS, Brinchmann JE (2013)
   Genome-wide map of quantified epigenetic changes during in vitro chondrogenic differentiation of primary human mesenchymal stem cells
   BMC Genomics, 14, 105
   DOI 10.1186/1471-2164-14-105, PubMed 23414147
6. Kuijjer ML, Peterse EF, van den Akker BE, Briaire-de Bruijn IH, Serra M, Meza-Zepeda LA, Myklebost O, Hassan AB, Hogendoorn PC, Cleton-Jansen AM (2013)
   IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma
   BMC Cancer, 13, 245
   DOI 10.1186/1471-2407-13-245, PubMed 23688189
7. Lauvrak SU, Munthe E, Kresse SH, Stratford EW, Namløs HM, Meza-Zepeda LA, Myklebost O (2013)
   Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes
   Br J Cancer, 109 (8), 2228-36
   DOI 10.1038/bjc.2013.549, PubMed 24064976
8. Nome T, Thomassen GO, Bruun J, Ahlquist T, Bakken AC, Hoff AM, Rognum T, Nesbakken A, Lorenz S, Sun J, Barros-Silva JD, Lind GE, Myklebost O, Teixeira MR, Meza-Zepeda LA, Lothe RA, Skotheim RI (2013)
   Common fusion transcripts identified in colorectal cancer cell lines by high-throughput RNA sequencing
   Transl Oncol, 6 (5), 546-53
   DOI 10.1593/tlo.13457, PubMed 24151535
9. Qu S, Olafsrud SM, Meza-Zepeda LA, Saatcioglu F (2013)
   Rapid gene expression changes in peripheral blood lymphocytes upon practice of a comprehensive yoga program
   PLoS One, 8 (4), e61910
   DOI 10.1371/journal.pone.0061910, PubMed 23613970
10. Sandberg CJ, Altschuler G, Jeong J, Strømme KK, Stangeland B, Murrell W, Grasmo-Wendler UH, Myklebost O, Helseth E, Vik-Mo EO, Hide W, Langmoen IA (2013)
    Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt- signaling and a fingerprint associated with clinical outcome
    Exp Cell Res, 319 (14), 2230-43
    DOI 10.1016/j.yexcr.2013.06.004, PubMed 23791939
11. Schee K, Lorenz S, Worren MM, Günther CC, Holden M, Hovig E, Fodstad O, Meza-Zepeda LA, Flatmark K (2013)
    Deep Sequencing the MicroRNA Transcriptome in Colorectal Cancer
    PLoS One, 8 (6), e66165
    DOI 10.1371/journal.pone.0066165, PubMed 23824282
12. Skårn M, Barøy T, Stratford EW, Myklebost O (2013)
    Epigenetic regulation and functional characterization of microRNA-142 in mesenchymal cells
    PLoS One, 8 (11), e79231
    DOI 10.1371/journal.pone.0079231, PubMed 24236112
13. Stratford EW, Bostad M, Castro R, Skarpen E, Berg K, Høgset A, Myklebost O, Selbo PK (2013)
    Photochemical internalization of CD133-targeting immunotoxins efficiently depletes sarcoma cells with stem-like properties and reduces tumorigenicity
    Biochim Biophys Acta, 1830 (8), 4235-43
    DOI 10.1016/j.bbagen.2013.04.033, PubMed 23643966
14. Stratford EW, Daffinrud J, Munthe E, Castro R, Waaler J, Krauss S, Myklebost O (2013)
    The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines
    Cancer Med, 3 (1), 36-46
    DOI 10.1002/cam4.170, PubMed 24403055
15. Wang P, Gao Q, Suo Z, Munthe E, Solberg S, Ma L, Wang M, Westerdaal NA, Kvalheim G, Gaudernack G (2013)
    Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines
    PLoS One, 8 (3), e57020 (Retracted)
    DOI 10.1371/journal.pone.0057020, PubMed 23469181

Publications 2012

1. Bjørnstad LG, Meza TJ, Otterlei M, Olafsrud SM, Meza-Zepeda LA, Falnes PØ (2012)
   Human ALKBH4 interacts with proteins associated with transcription
   PLoS One, 7 (11), e49045
   DOI 10.1371/journal.pone.0049045, PubMed 23145062
2. Chymkowitch P, Eldholm V, Lorenz S, Zimmermann C, Lindvall JM, Bjørås M, Meza-Zepeda LA, Enserink JM (2012)
   Cdc28 kinase activity regulates the basal transcription machinery at a subset of genes
   Proc Natl Acad Sci U S A, 109 (26), 10450-5
   DOI 10.1073/pnas.1200067109, PubMed 22689984
3. Kresse SH, Rydbeck H, Skårn M, Namløs HM, Barragan-Polania AH, Cleton-Jansen AM, Serra M, Liestøl K, Hogendoorn PC, Hovig E, Myklebost O, Meza-Zepeda LA (2012)
   Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma
   PLoS One, 7 (11), e48262
   DOI 10.1371/journal.pone.0048262, PubMed 23144859
4. Kuijjer ML, Rydbeck H, Kresse SH, Buddingh EP, Lid AB, Roelofs H, Bürger H, Myklebost O, Hogendoorn PC, Meza-Zepeda LA, Cleton-Jansen AM (2012)
   Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data
   Genes Chromosomes Cancer, 51 (7), 696-706
   DOI 10.1002/gcc.21956, PubMed 22454324
5. Namløs HM, Kresse SH, Müller CR, Henriksen J, Holdhus R, Sæter G, Bruland OS, Bjerkehagen B, Steen VM, Myklebost O (2012)
   Global gene expression profiling of human osteosarcomas reveals metastasis-associated chemokine pattern
   Sarcoma, 2012, 639038
   DOI 10.1155/2012/639038, PubMed 22518090
6. Namløs HM, Meza-Zepeda LA, Barøy T, Østensen IH, Kresse SH, Kuijjer ML, Serra M, Bürger H, Cleton-Jansen AM, Myklebost O (2012)
   Modulation of the osteosarcoma expression phenotype by microRNAs
   PLoS One, 7 (10), e48086
   DOI 10.1371/journal.pone.0048086, PubMed 23133552
7. Ohnstad HO, Castro R, Sun J, Heintz KM, Vassilev LT, Bjerkehagen B, Kresse SH, Meza-Zepeda LA, Myklebost O (2012)
   Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma
   Cancer, 119 (5), 1013-22
   DOI 10.1002/cncr.27837, PubMed 23165797
8. Reikvam DH, Derrien M, Islam R, Erofeev A, Grcic V, Sandvik A, Gaustad P, Meza-Zepeda LA, Jahnsen FL, Smidt H, Johansen FE (2012)
   Epithelial-microbial crosstalk in polymeric Ig receptor deficient mice
   Eur J Immunol, 42 (11), 2959-70
   DOI 10.1002/eji.201242543, PubMed 22865203
9. Stratford EW, Castro R, Daffinrud J, Skårn M, Lauvrak S, Munthe E, Myklebost O (2012)
   Characterization of liposarcoma cell lines for preclinical and biological studies
   Sarcoma, 2012, 148614
   DOI 10.1155/2012/148614, PubMed 22911243

Publications 2011

1. Buddingh EP, Kuijjer ML, Duim RA, Bürger H, Agelopoulos K, Myklebost O, Serra M, Mertens F, Hogendoorn PC, Lankester AC, Cleton-Jansen AM (2011)
   Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents
   Clin Cancer Res, 17 (8), 2110-9
   DOI 10.1158/1078-0432.CCR-10-2047, PubMed 21372215
2. Dahlback HS, Brandal P, Krossnes BK, Fric R, Meling TR, Meza-Zepeda LA, Danielsen HE, Heim S (2011)
   Multiple chromosomal monosomies are characteristic of giant cell ependymoma
   Hum Pathol, 42 (12), 2042-6
   DOI 10.1016/j.humpath.2011.02.012, PubMed 21683982
3. Hjortland GO, Meza-Zepeda LA, Beiske K, Ree AH, Tveito S, Hoifodt H, Bohler PJ, Hole KH, Myklebost O, Fodstad O, Smeland S, Hovig E (2011)
   Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma
   BMC Cancer, 11, 455
   DOI 10.1186/1471-2407-11-455, PubMed 22014070
4. Jin Y, Zhen Y, Haugsten EM, Wiedlocha A (2011)
   The driver of malignancy in KG-1a leukemic cells, FGFR1OP2-FGFR1, encodes an HSP90 addicted oncoprotein
   Cell Signal, 23 (11), 1758-66
   DOI 10.1016/j.cellsig.2011.06.010, PubMed 21745565
5. Kresse SH, Meza-Zepeda LA, Machado I, Llombart-Bosch A, Myklebost O (2011)
   Preclinical xenograft models of human sarcoma show nonrandom loss of aberrations
   Cancer, 118 (2), 558-70
   DOI 10.1002/cncr.26276, PubMed 21713766
6. Kuijjer ML, Namløs HM, Hauben EI, Machado I, Kresse SH, Serra M, Llombart-Bosch A, Hogendoorn PC, Meza-Zepeda LA, Myklebost O, Cleton-Jansen AM (2011)
   mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts
   BMC Med Genomics, 4, 66
   DOI 10.1186/1755-8794-4-66, PubMed 21933437
7. Ohnstad HO, Paulsen EB, Noordhuis P, Berg M, Lothe RA, Vassilev LT, Myklebost O (2011)
   MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
   BMC Cancer, 11, 211:1-11
   DOI 10.1186/1471-2407-11-211, PubMed 21624110
8. Reikvam DH, Erofeev A, Sandvik A, Grcic V, Jahnsen FL, Gaustad P, McCoy KD, Macpherson AJ, Meza-Zepeda LA, Johansen FE (2011)
   Depletion of murine intestinal microbiota: effects on gut mucosa and epithelial gene expression
   PLoS One, 6 (3), e17996
   DOI 10.1371/journal.pone.0017996, PubMed 21445311
9. Skårn M, Namløs HM, Noordhuis P, Wang MY, Meza-Zepeda LA, Myklebost O (2011)
   Adipocyte differentiation of human bone marrow-derived stromal cells is modulated by microRNA-155, microRNA-221, and microRNA-222
   Stem Cells Dev, 21 (6), 873-83
   DOI 10.1089/scd.2010.0503, PubMed 21756067
10. Stratford EW, Castro R, Wennerstrom A, Holm R, Munthe E, Lauvrak S, Bjerkehagen B, Myklebost O (2011)
    Liposarcoma Cells with Aldefluor and CD133 Activity have a Cancer Stem Cell Potential
    Clin Sarcoma Res, 1 (1), 8
    DOI 10.1186/2045-3329-1-8, PubMed 22612877
11. Thomas DM, Wilhelm M, Cleton-Jansen AM, Dirksen U, Entz-Werlé N, Gelderblom H, Hassan B, Jürgens H, Koster J, Kovar H, Lankester AC, Lewis IJ, Myklebost O, Nathrath MH, Picci P, Whelan JS, Hogendoorn PC, Bielack SS (2011)
    Workshop Report on the European Bone Sarcoma Networking Meeting: Integration of Clinical Trials with Tumor Biology
    J Adolesc Young Adult Oncol, 1 (3), 118-23
    DOI 10.1089/jayao.2012.0005, PubMed 26811922
12. Wesche J, Haglund K, Haugsten EM (2011)
    Fibroblast growth factors and their receptors in cancer
    Biochem J, 437 (2), 199-213
    DOI 10.1042/BJ20101603, PubMed 21711248

Publications 2010

1. Eide MB, Liestøl K, Lingjaerde OC, Hystad ME, Kresse SH, Meza-Zepeda L, Myklebost O, Trøen G, Aamot HV, Holte H, Smeland EB, Delabie J (2010)
   Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones
   Blood, 116 (9), 1489-97
   DOI 10.1182/blood-2010-03-272278, PubMed 20505157
2. Henriksen J, Stabell M, Meza-Zepeda LA, Lauvrak SA, Kassem M, Myklebost O (2010)
   Identification of target genes for wild type and truncated HMGA2 in mesenchymal stem-like cells
   BMC Cancer, 10, 329
   DOI 10.1186/1471-2407-10-329, PubMed 20576167
3. Katayama T, Arakawa K, Nakao M, Ono K, Aoki-Kinoshita KF, Yamamoto Y, Yamaguchi A, Kawashima S, Chun HW, Aerts J, Aranda B, Barboza LH, Bonnal RJ, Bruskiewich R, Bryne JC, Fernández JM, Funahashi A, Gordon PM, Goto N, Groscurth A, Gutteridge A, Holland R, Kano Y, Kawas EA, Kerhornou A et al. (2010)
   The DBCLS BioHackathon: standardization and interoperability for bioinformatics web services and workflows. The DBCLS BioHackathon Consortium*
   J Biomed Semantics, 1 (1), 8
   DOI 10.1186/2041-1480-1-8, PubMed 20727200
4. Kresse SH, Ohnstad HO, Bjerkehagen B, Myklebost O, Meza-Zepeda LA (2010)
   DNA copy number changes in human malignant fibrous histiocytomas by array comparative genomic hybridisation
   PLoS One, 5 (11), e15378
   DOI 10.1371/journal.pone.0015378, PubMed 21085701
5. Kresse SH, Szuhai K, Barragan-Polania AH, Rydbeck H, Cleton-Jansen AM, Myklebost O, Meza-Zepeda LA (2010)
   Evaluation of high-resolution microarray platforms for genomic profiling of bone tumours
   BMC Res Notes, 3, 223
   DOI 10.1186/1756-0500-3-223, PubMed 20691109
6. Mayordomo E, Machado I, Giner F, Kresse SH, Myklebost O, Carda C, Navarro S, Llombart-Bosch A (2010)
   A tissue microarray study of osteosarcoma: histopathologic and immunohistochemical validation of xenotransplanted tumors as preclinical models
   Appl Immunohistochem Mol Morphol, 18 (5), 453-61
   DOI 10.1097/PAI.0b013e3181daace3, PubMed 20436344
7. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, Cleton-Jansen AM, Hogendoorn PC, Buerger H, Aigner T, Gabbert HE, Poremba C (2010)
   Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort
   Genes Chromosomes Cancer, 49 (1), 40-51
   DOI 10.1002/gcc.20717, PubMed 19787792
8. Soler E, Andrieu-Soler C, de Boer E, Bryne JC, Thongjuea S, Stadhouders R, Palstra RJ, Stevens M, Kockx C, van IJcken W, Hou J, Steinhoff C, Rijkers E, Lenhard B, Grosveld F (2010)
   The genome-wide dynamics of the binding of Ldb1 complexes during erythroid differentiation (vol 24, pg 277, 2010)
   Genes Dev., 24 (6), 623
9. Tenstad E, Tourovskaia A, Folch A, Myklebost O, Rian E (2010)
   Extensive adipogenic and osteogenic differentiation of patterned human mesenchymal stem cells in a microfluidic device
   Lab Chip, 10 (11), 1401-1409
   DOI 10.1039/b926738g, PubMed 20386793

Publications 2009

1. Kresse SH, Ohnstad HO, Paulsen EB, Bjerkehagen B, Szuhai K, Serra M, Schaefer KL, Myklebost O, Meza-Zepeda LA (2009)
   LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization
   Genes Chromosomes Cancer, 48 (8), 679-93
   DOI 10.1002/gcc.20675, PubMed 19441093
2. Myklebost O, Noordhuis P (2009)
   Bone marrow stroma cells regulate TIEG1 expression in acute lymphoblastic leukemia cells: Role of TGF beta/BMP-6 and TIEG1 in chemotherapy escape. (vol 123, pg 2759, 2008)
   Int. J. Cancer, 124 (9), 2250
   DOI 10.1002/ijc.24300
3. Våtsveen TK, Tian E, Kresse SH, Meza-Zepeda LA, Gabrea A, Glebov O, Dai HY, Sundan A, Kuehl WM, Børset M (2009)
   OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus
   Leuk Res, 33 (12), 1670-7
   DOI 10.1016/j.leukres.2009.03.001, PubMed 19395026

Publications 2008

1. Kresse SH, Skårn M, Ohnstad HO, Namløs HM, Bjerkehagen B, Myklebost O, Meza-Zepeda LA (2008)
   DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH
   Mol Cancer, 7, 48
   DOI 10.1186/1476-4598-7-48, PubMed 18522746
2. Larsen E, Kleppa L, Meza TJ, Meza-Zepeda LA, Rada C, Castellanos CG, Lien GF, Nesse GJ, Neuberger MS, Laerdahl JK, William Doughty R, Klungland A (2008)
   Early-onset lymphoma and extensive embryonic apoptosis in two domain-specific Fen1 mice mutants
   Cancer Res, 68 (12), 4571-9
   DOI 10.1158/0008-5472.CAN-08-0168, PubMed 18559501
3. Lybaek H, Meza-Zepeda LA, Kresse SH, Høysaeter T, Steen VM, Houge G (2008)
   Array-CGH fine mapping of minor and cryptic HR-CGH detected genomic imbalances in 80 out of 590 patients with abnormal development
   Eur J Hum Genet, 16 (11), 1318-28
   DOI 10.1038/ejhg.2008.78, PubMed 18461090
4. Lyng H, Lando M, Brøvig RS, Svendsrud DH, Johansen M, Galteland E, Brustugun OT, Meza-Zepeda LA, Myklebost O, Kristensen GB, Hovig E, Stokke T (2008)
   GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data
   Genome Biol, 9 (5), R86
   DOI 10.1186/gb-2008-9-5-r86, PubMed 18500990
5. Meza-Zepeda LA, Noer A, Dahl JA, Micci F, Myklebost O, Collas P (2008)
   High-resolution analysis of genetic stability of human adipose tissue stem cells cultured to senescence
   J Cell Mol Med, 12 (2), 553-63
   DOI 10.1111/j.1582-4934.2007.00146.x, PubMed 18419597
6. Roman E, Meza-Zepeda LA, Kresse SH, Myklebost O, Vasstrand EN, Ibrahim SO (2008)
   Chromosomal aberrations in head and neck squamous cell carcinomas in Norwegian and Sudanese populations by array comparative genomic hybridization
   Oncol Rep, 20 (4), 825-43
   DOI 10.3892/or_00000080, PubMed 18813824

Publications 2007

1. Francis P, Namløs HM, Müller C, Edén P, Fernebro J, Berner JM, Bjerkehagen B, Akerman M, Bendahl PO, Isinger A, Rydholm A, Myklebost O, Nilbert M (2007)
   Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential
   BMC Genomics, 8, 73
   DOI 10.1186/1471-2164-8-73, PubMed 17359542
2. Kleivi K, Lind GE, Diep CB, Meling GI, Brandal LT, Nesland JM, Myklebost O, Rognum TO, Giercksky KE, Skotheim RI, Lothe RA (2007)
   Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses
   Mol Cancer, 6, 2
   DOI 10.1186/1476-4598-6-2, PubMed 17201907
3. Müller CR, Paulsen EB, Noordhuis P, Pedeutour F, Saeter G, Myklebost O (2007)
   Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A
   Int J Cancer, 121 (1), 199-205
   DOI 10.1002/ijc.22643, PubMed 17354236
4. Zangani MM, Frøyland M, Qiu GY, Meza-Zepeda LA, Kutok JL, Thompson KM, Munthe LA, Bogen B (2007)
   Lymphomas can develop from B cells chronically helped by idiotype-specific T cells
   J Exp Med, 204 (5), 1181-91
   DOI 10.1084/jem.20061220, PubMed 17485509

Publications 2006

1. Berner JM, Muller CR, Holden M, Wang J, Hovig E, Myklebost O (2006)
   Sampling effects on gene expression data from a human tumour xenograft
   Scand. J. Lab. Anim. Sci., 33 (1), 17-30
2. MAQC Consortium, Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de Longueville F, Kawasaki ES, Lee KY, Luo Y, Sun YA, Willey JC, Setterquist RA, Fischer GM, Tong W, Dragan YP, Dix DJ, Frueh FW, Goodsaid FM, Herman D, Jensen RV, Johnson CD, Lobenhofer EK et al. (2006)
   The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements
   Nat Biotechnol, 24 (9), 1151-61
   DOI 10.1038/nbt1239, PubMed 16964229
3. Meza-Zepeda LA, Kresse SH, Barragan-Polania AH, Bjerkehagen B, Ohnstad HO, Namløs HM, Wang J, Kristiansen BE, Myklebost O (2006)
   Array comparative genomic hybridization reveals distinct DNA copy number differences between gastrointestinal stromal tumors and leiomyosarcomas
   Cancer Res, 66 (18), 8984-93
   DOI 10.1158/0008-5472.CAN-06-1972, PubMed 16982739
4. Ree AH, Stokke T, Bratland A, Patzke S, Nome RV, Folkvord S, Meza-Zepeda LA, Flatmark K, Fodstad O, Andersson Y (2006)
   DNA damage responses in cell cycle G2 phase and mitosis--tracking and targeting
   Anticancer Res, 26 (3A), 1909-16
   PubMed 16827124
5. Sivertsen EA, Galteland E, Mu D, Holte H, Meza-Zepeda L, Myklebost O, Patzke S, Smeland EB, Stokke T (2006)
   Gain of chromosome 6p is an infrequent cause of increased PIM1 expression in B-cell non-Hodgkin's lymphomas
   Leukemia, 20 (3), 539-42
   DOI 10.1038/sj.leu.2404094, PubMed 16437153
6. Sørensen V, Wiedlocha A, Haugsten EM, Khnykin D, Wesche J, Olsnes S (2006)
   Different abilities of the four FGFRs to mediate FGF-1 translocation are linked to differences in the receptor C-terminal tail
   J Cell Sci, 119 (Pt 20), 4332-41
   DOI 10.1242/jcs.03209, PubMed 17003104
7. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, Myklebost O, Heimbrook DC, Vassilev LT (2006)
   Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
   Proc Natl Acad Sci U S A, 103 (6), 1888-93
   DOI 10.1073/pnas.0507493103, PubMed 16443686

Publications 2005

1. Agesen TH, Flørenes VA, Molenaar WM, Lind GE, Berner JM, Plaat BE, Komdeur R, Myklebost O, van den Berg E, Lothe RA (2005)
   Expression patterns of cell cycle components in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors
   J Neuropathol Exp Neurol, 64 (1), 74-81
   DOI 10.1093/jnen/64.1.74, PubMed 15715087
2. Bjerkehagen B, Myklebost O (2005)
   [Molecular genetics in the diagnosis of bone and soft tissue tumours]
   Tidsskr Nor Laegeforen, 125 (23), 3286-9
   PubMed 16327856
3. Galteland E, Sivertsen EA, Svendsrud DH, Smedshammer L, Kresse SH, Meza-Zepeda LA, Myklebost O, Suo Z, Mu D, Deangelis PM, Stokke T (2005)
   Translocation t(14;18) and gain of chromosome 18/BCL2: effects on BCL2 expression and apoptosis in B-cell non-Hodgkin's lymphomas
   Leukemia, 19 (12), 2313-23
   DOI 10.1038/sj.leu.2403954, PubMed 16193090
4. Kresse SH, Berner JM, Meza-Zepeda LA, Gregory SG, Kuo WL, Gray JW, Forus A, Myklebost O (2005)
   Mapping and characterization of the amplicon near APOA2 in 1q23 in human sarcomas by FISH and array CGH
   Mol Cancer, 4, 39
   DOI 10.1186/1476-4598-4-39, PubMed 16274472
5. Lyng H, Landsverk KS, Kristiansen E, DeAngelis PM, Ree AH, Myklebost O, Hovig E, Stokke T (2005)
   Response of malignant B lymphocytes to ionizing radiation: gene expression and genotype
   Int J Cancer, 115 (6), 935-42
   DOI 10.1002/ijc.20962, PubMed 15723354
6. Nygaard V, Holden M, Løland A, Langaas M, Myklebost O, Hovig E (2005)
   Limitations of mRNA amplification from small-size cell samples
   BMC Genomics, 6, 147
   DOI 10.1186/1471-2164-6-147, PubMed 16253144

Publications 2004

1. Cekaite L, Haug O, Myklebost O, Aldrin M, Østenstad B, Holden M, Frigessi A, Hovig E, Sioud M (2004)
   Analysis of the humoral immune response to immunoselected phage-displayed peptides by a microarray-based method
   Proteomics, 4 (9), 2572-82
   DOI 10.1002/pmic.200300768, PubMed 15352232
2. Lyng H, Badiee A, Svendsrud DH, Hovig E, Myklebost O, Stokke T (2004)
   Profound influence of microarray scanner characteristics on gene expression ratios: analysis and procedure for correction
   BMC Genomics, 5 (1), 10
   DOI 10.1186/1471-2164-5-10, PubMed 15018648
3. Mathiesen G, Namløs HM, Risøen PA, Axelsson L, Eijsink VG (2004)
   Use of bacteriocin promoters for gene expression in Lactobacillus plantarum C11
   J Appl Microbiol, 96 (4), 819-27
   DOI 10.1111/j.1365-2672.2004.02206.x, PubMed 15012821
4. Myklebost O (2004)
   Putting Norway on the gene-therapy map
   Nature, 429 (6988), 129
   DOI 10.1038/429129b, PubMed 15141186
5. Nilbert M, Meza-Zepeda LA, Francis P, Berner JM, Namløs HM, Fernebro J, Myklebost O (2004)
   Lessons from genetic profiling in soft tissue sarcomas
   Acta Orthop Scand Suppl, 75 (311), 35-50
   DOI 10.1080/00016470410001708310, PubMed 15188664
6. Nilsson M, Meza-Zepeda LA, Mertens F, Forus A, Myklebost O, Mandahl N (2004)
   Amplification of chromosome 1 sequences in lipomatous tumors and other sarcomas
   Int J Cancer, 109 (3), 363-9
   DOI 10.1002/ijc.11716, PubMed 14961574
7. Trøen G, Nygaard V, Jenssen TK, Ikonomou IM, Tierens A, Matutes E, Gruszka-Westwood A, Catovsky D, Myklebost O, Lauritzsen G, Hovig E, Delabie J (2004)
   Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma
   J Mol Diagn, 6 (4), 297-307
   DOI 10.1016/S1525-1578(10)60525-9, PubMed 15507668
8. Wang J, Meza-Zepeda LA, Kresse SH, Myklebost O (2004)
   M-CGH: analysing microarray-based CGH experiments
   BMC Bioinformatics, 5, 74
   DOI 10.1186/1471-2105-5-74, PubMed 15189572

Publications 2003

1. Andersen K, Smith-Sørensen B, Pedersen KB, Hovig E, Myklebost O, Fodstad Ø, Maelandsmo GM (2003)
   Interferon-gamma suppresses S100A4 transcription independently of apoptosis or cell cycle arrest
   Br J Cancer, 88 (12), 1995-2001
   DOI 10.1038/sj.bjc.6600998, PubMed 12799648
2. Henriksen J, Aagesen TH, Maelandsmo GM, Lothe RA, Myklebost O, Forus A (2003)
   Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation
   Oncogene, 22 (34), 5358-61
   DOI 10.1038/sj.onc.1206671, PubMed 12917637
3. Maire G, Forus A, Foa C, Bjerkehagen B, Mainguené C, Kresse SH, Myklebost O, Pedeutour F (2003)
   11q13 alterations in two cases of hibernoma: large heterozygous deletions and rearrangement breakpoints near GARP in 11q13.5
   Genes Chromosomes Cancer, 37 (4), 389-95
   DOI 10.1002/gcc.10223, PubMed 12800150
4. Nygaard V, Løland A, Holden M, Langaas M, Rue H, Liu F, Myklebost O, Fodstad Ø, Hovig E, Smith-Sørensen B (2003)
   Effects of mRNA amplification on gene expression ratios in cDNA experiments estimated by analysis of variance
   BMC Genomics, 4 (1), 11
   DOI 10.1186/1471-2164-4-11, PubMed 12659661
5. Wang J, Bø TH, Jonassen I, Myklebost O, Hovig E (2003)
   Tumor classification and marker gene prediction by feature selection and fuzzy c-means clustering using microarray data
   BMC Bioinformatics, 4, 60
   DOI 10.1186/1471-2105-4-60, PubMed 14651757
6. Wang J, Myklebost O, Hovig E (2003)
   MGraph: graphical models for microarray data analysis
   Bioinformatics, 19 (17), 2210-1
   DOI 10.1093/bioinformatics/btg298, PubMed 14630649

Publications 2002

1. Jenssen TK, Langaas M, Kuo WP, Smith-Sørensen B, Myklebost O, Hovig E (2002)
   Analysis of repeatability in spotted cDNA microarrays
   Nucleic Acids Res, 30 (14), 3235-44
   DOI 10.1093/nar/gkf441, PubMed 12136105
2. Meza-Zepeda LA, Forus A, Lygren B, Dahlberg AB, Godager LH, South AP, Marenholz I, Lioumi M, Flørenes VA, Maelandsmo GM, Serra M, Mischke D, Nizetic D, Ragoussis J, Tarkkanen M, Nesland JM, Knuutila S, Myklebost O (2002)
   Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21
   Oncogene, 21 (14), 2261-9
   DOI 10.1038/sj.onc.1205339, PubMed 11948409
3. Meza TJ, Stangeland B, Mercy IS, Skårn M, Nymoen DA, Berg A, Butenko MA, Håkelien AM, Haslekås C, Meza-Zepeda LA, Aalen RB (2002)
   Analyses of single-copy Arabidopsis T-DNA-transformed lines show that the presence of vector backbone sequences, short inverted repeats and DNA methylation is not sufficient or necessary for the induction of transgene silencing
   Nucleic Acids Res, 30 (20), 4556-66
   DOI 10.1093/nar/gkf568, PubMed 12384603
4. Wang J, Delabie J, Aasheim H, Smeland E, Myklebost O (2002)
   Clustering of the SOM easily reveals distinct gene expression patterns: results of a reanalysis of lymphoma study
   BMC Bioinformatics, 3, 36
   DOI 10.1186/1471-2105-3-36, PubMed 12445336
5. Wang J, Nygaard V, Smith-Sørensen B, Hovig E, Myklebost O (2002)
   MArray: analysing single, replicated or reversed microarray experiments
   Bioinformatics, 18 (8), 1139-40
   DOI 10.1093/bioinformatics/18.8.1139, PubMed 12176840
6. Xie Y, Skytting B, Nilsson G, Grimer RJ, Mangham CD, Fisher C, Shipley J, Bjerkehagen B, Myklebost O, Larsson O (2002)
   The SYT-SSX1 fusion type of synovial sarcoma is associated with increased expression of cyclin A and D1. A link between t(X;18)(p11.2; q11.2) and the cell cycle machinery
   Oncogene, 21 (37), 5791-6
   DOI 10.1038/sj.onc.1205700, PubMed 12173050

Publications 2001

1. Forus A, Bjerkehagen B, Sirvent N, Meza-Zepeda LA, Coindre JM, Berner JM, Myklebost O, Pedeutour F (2001)
   A well-differentiated liposarcoma with a new type of chromosome 12-derived markers
   Cancer Genet Cytogenet, 131 (1), 13-8
   DOI 10.1016/s0165-4608(01)00516-7, PubMed 11734312
2. Forus A, D'Angelo A, Henriksen J, Merla G, Maelandsmo GM, Flørenes VA, Olivieri S, Bjerkehagen B, Meza-Zepeda LA, del Vecchio Blanco F, Müller C, Sanvito F, Kononen J, Nesland JM, Fodstad Ø, Reymond A, Kallioniemi OP, Arrigoni G, Ballabio A, Myklebost O, Zollo M (2001)
   Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas-a possible mechanism for altering the nm23-H1 activity
   Oncogene, 20 (47), 6881-90
   DOI 10.1038/sj.onc.1204874, PubMed 11687967
3. Forus A, Larramendy ML, Meza-Zepeda LA, Bjerkehagen B, Godager LH, Dahlberg AB, Saeter G, Knuutila S, Myklebost O (2001)
   Dedifferentiation of a well-differentiated liposarcoma to a highly malignant metastatic osteosarcoma: amplification of 12q14 at all stages and gain of 1q22-q24 associated with metastases
   Cancer Genet Cytogenet, 125 (2), 100-11
   DOI 10.1016/s0165-4608(00)00369-1, PubMed 11369052
4. Forus A, Sørlie T, Børresen-Dale AL, Myklebost O (2001)
   [Microarray technology--potential in cancer research]
   Tidsskr Nor Laegeforen, 121 (21), 2498-503
   PubMed 11875927
5. Hovig E, Myklebost O, Aamdal S, Smeland EB (2001)
   [Gene therapy in cancer]
   Tidsskr Nor Laegeforen, 121 (4), 482-8
   PubMed 11255868
6. Meza-Zepeda LA, Berner JM, Henriksen J, South AP, Pedeutour F, Dahlberg AB, Godager LH, Nizetic D, Forus A, Myklebost O (2001)
   Ectopic sequences from truncated HMGIC in liposarcomas are derived from various amplified chromosomal regions
   Genes Chromosomes Cancer, 31 (3), 264-73
   DOI 10.1002/gcc.1143, PubMed 11391797
7. Sandvik AK, Støren O, Nørsett K, Laegreid A, Børresen-Dale AL, Myklebost O (2001)
   [Measurement of gene activity by DNA microarrays]
   Tidsskr Nor Laegeforen, 121 (10), 1225-8
   PubMed 11402749

Publications 2000

1. Simons A, Schepens M, Jeuken J, Sprenger S, van de Zande G, Bjerkehagen B, Forus A, Weibolt V, Molenaar I, van den Berg E, Myklebost O, Bridge J, van Kessel AG, Suijkerbuijk R (2000)
   Frequent loss of 9p21 (p16(INK4A)) and other genomic imbalances in human malignant fibrous histiocytoma
   Cancer Genet Cytogenet, 118 (2), 89-98
   DOI 10.1016/s0165-4608(99)00178-8, PubMed 10748288
2. Sirvent N, Forus A, Lescaut W, Burel F, Benzaken S, Chazal M, Bourgeon A, Vermeesch JR, Myklebost O, Turc-Carel C, Ayraud N, Coindre JM, Pedeutour F (2000)
   Characterization of centromere alterations in liposarcomas
   Genes Chromosomes Cancer, 29 (2), 117-29
   DOI 10.1002/1098-2264(2000)9999:9999<::aid-gcc1014>3.0.co;2-q, PubMed 10959091

Publications 1999

1. Berner JM, Sørlie T, Mertens F, Henriksen J, Saeter G, Mandahl N, Brøgger A, Myklebost O, Lothe RA (1999)
   Chromosome band 9p21 is frequently altered in malignant peripheral nerve sheath tumors: studies of CDKN2A and other genes of the pRB pathway
   Genes Chromosomes Cancer, 26 (2), 151-60
   DOI 10.1002/(SICI)1098-2264(199910)26:2<151::AID-GCC7>3.0.CO;2-A, PubMed 10469453
2. Forus A, Høifødt HK, Overli GE, Myklebost O, Fodstad O (1999)
   Sensitive fluorescent in situ hybridisation method for the characterisation of breast cancer cells in bone marrow aspirates
   Mol Pathol, 52 (2), 68-74
   DOI 10.1136/mp.52.2.68, PubMed 10474684
3. Pedeutour F, Forus A, Coindre JM, Berner JM, Nicolo G, Michiels JF, Terrier P, Ranchere-Vince D, Collin F, Myklebost O, Turc-Carel C (1999)
   Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors
   Genes Chromosomes Cancer, 24 (1), 30-41
   DOI 10.1002/(SICI)1098-2264(199901)24:1<30::AID-GCC5>3.3.CO;2-G, PubMed 9892106
4. Ree AH, Tvermyr M, Engebraaten O, Rooman M, Røsok O, Hovig E, Meza-Zepeda LA, Bruland OS, Fodstad O (1999)
   Expression of a novel factor in human breast cancer cells with metastatic potential
   Cancer Res, 59 (18), 4675-80
   PubMed 10493524
5. Simons A, Schepens M, Forus A, Godager L, van Asseldonk M, Myklebost O, van Kessel AG (1999)
   A novel chromosomal region of allelic loss, 4q32-q34, in human osteosarcomas revealed by representational difference analysis
   Genes Chromosomes Cancer, 26 (2), 115-24
   DOI 10.1002/(SICI)1098-2264(199910)26:2<115::AID-GCC3>3.0.CO;2-E, PubMed 10469449
6. Wolf M, Tarkkanen M, Hulsebos T, Larramendy ML, Forus A, Myklebost O, Aaltonen LA, Elomaa I, Knuutila S (1999)
   Characterization of the 17p amplicon in human sarcomas: microsatellite marker analysis
   Int J Cancer, 82 (3), 329-33
   DOI 10.1002/(sici)1097-0215(19990730)82:3<329::aid-ijc4>3.0.co;2-1, PubMed 10399948

Publications 1998

1. Forus A, Berner JM, Meza-Zepeda LA, Saeter G, Mischke D, Fodstad O, Myklebost O (1998)
   Molecular characterization of a novel amplicon at 1q21-q22 frequently observed in human sarcomas
   Br J Cancer, 78 (4), 495-503
   DOI 10.1038/bjc.1998.521, PubMed 9716033
2. Myklebost O (1998)
   GLI gene and rhabdomyosarcoma
   Nat Med, 4 (8), 869
   DOI 10.1038/nm0898-869c, PubMed 9701218

Publications 1997

1. Armengol G, Tarkkanen M, Virolainen M, Forus A, Valle J, Böhling T, Asko-Seljavaara S, Blomqvist C, Elomaa I, Karaharju E, Kivioja AH, Siimes MA, Tukiainen E, Caballín MR, Myklebost O, Knuutila S (1997)
   Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization
   Br J Cancer, 75 (10), 1403-9
   DOI 10.1038/bjc.1997.242, PubMed 9166930
2. Berner JM, Meza-Zepeda LA, Kools PF, Forus A, Schoenmakers EF, Van de Ven WJ, Fodstad O, Myklebost O (1997)
   HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas
   Oncogene, 14 (24), 2935-41
   DOI 10.1038/sj.onc.1201135, PubMed 9205100
3. Geurts van Kessel A, dos Santos NR, Simons A, de Bruijn D, Forus A, Fodstad O, Myklebost O, Balemans M, Baats E, Olde Weghuis D, Suijkerbuijk RF, van den Berg E, Molenaar WM, de Leeuw B (1997)
   Molecular cytogenetics of bone and soft tissue tumors
   Cancer Genet Cytogenet, 95 (1), 67-73
   DOI 10.1016/s0165-4608(96)00241-5, PubMed 9140455
4. Wolf M, Aaltonen LA, Szymanska J, Tarkkanen M, Blomqvist C, Berner JM, Myklebost O, Knuutila S (1997)
   Complexity of 12q13-22 amplicon in liposarcoma: microsatellite repeat analysis
   Genes Chromosomes Cancer, 18 (1), 66-70
   DOI 10.1002/(sici)1098-2264(199701)18:1<66::aid-gcc8>3.0.co;2-#, PubMed 8993982

Publications 1996

1. Berner JM, Forus A, Elkahloun A, Meltzer PS, Fodstad O, Myklebost O (1996)
   Separate amplified regions encompassing CDK4 and MDM2 in human sarcomas
   Genes Chromosomes Cancer, 17 (4), 254-9
   DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2, PubMed 8946207
2. Maelandsmo GM, Hovig E, Skrede M, Engebraaten O, Flørenes VA, Myklebost O, Grigorian M, Lukanidin E, Scanlon KJ, Fodstad O (1996)
   Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme
   Cancer Res, 56 (23), 5490-8
   PubMed 8968106
3. Myklebost O (1996)
   First for biotech
   Nature, 384 (6606), 208
   DOI 10.1038/384208b0, PubMed 8918866

Publications 1995

1. Forus A, Weghuis DO, Smeets D, Fodstad O, Myklebost O, Geurts van Kessel A (1995)
   Comparative genomic hybridization analysis of human sarcomas: II. Identification of novel amplicons at 6p and 17p in osteosarcomas
   Genes Chromosomes Cancer, 14 (1), 15-21
   DOI 10.1002/gcc.2870140104, PubMed 8527379
2. Forus A, Weghuis DO, Smeets D, Fodstad O, Myklebost O, van Kessel AG (1995)
   Comparative genomic hybridization analysis of human sarcomas: I. Occurrence of genomic imbalances and identification of a novel major amplicon at 1q21-q22 in soft tissue sarcomas
   Genes Chromosomes Cancer, 14 (1), 8-14
   DOI 10.1002/gcc.2870140103, PubMed 8527390
3. Kulseth MA, Krajci P, Myklebost O, Rogne S (1995)
   Cloning and characterization of two forms of bovine polymeric immunoglobulin receptor cDNA
   DNA Cell Biol, 14 (3), 251-6
   DOI 10.1089/dna.1995.14.251, PubMed 7880445
4. Maelandsmo GM, Berner JM, Flørenes VA, Forus A, Hovig E, Fodstad O, Myklebost O (1995)
   Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas--relationship to amplification and mRNA levels of CDK4 and CCND1
   Br J Cancer, 72 (2), 393-8
   DOI 10.1038/bjc.1995.344, PubMed 7640224
5. Van Roy N, Forus A, Myklebost O, Cheng NC, Versteeg R, Speleman F (1995)
   Identification of two distinct chromosome 12-derived amplification units in neuroblastoma cell line NGP
   Cancer Genet Cytogenet, 82 (2), 151-4
   DOI 10.1016/0165-4608(95)00034-m, PubMed 7664245

Publications 1994

1. Flørenes VA, Holm R, Myklebost O, Lendahl U, Fodstad O (1994)
   Expression of the neuroectodermal intermediate filament nestin in human melanomas
   Cancer Res, 54 (2), 354-6
   PubMed 8275467
2. Flørenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstad O (1994)
   MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status
   J Natl Cancer Inst, 86 (17), 1297-302
   DOI 10.1093/jnci/86.17.1297, PubMed 8064888
3. Forus A, Flørenes VA, Maelandsmo GM, Fodstad O, Myklebost O (1994)
   The protooncogene CHOP/GADD153, involved in growth arrest and DNA damage response, is amplified in a subset of human sarcomas
   Cancer Genet Cytogenet, 78 (2), 165-71
   DOI 10.1016/0165-4608(94)90085-x, PubMed 7828148
4. Forus A, Kools PF, Schoenmakers EF, Van de Ven WJ, Myklebost O (1994)
   A long range restriction map spanning the myxoid liposarcoma breakpoint in the q13-14 region of human chromosome 12
   Hum Genet, 94 (3), 259-64
   DOI 10.1007/BF00208280, PubMed 8076941
5. Suijkerbuijk RF, Olde Weghuis DE, Van den Berg M, Pedeutour F, Forus A, Myklebost O, Glier C, Turc-Carel C, Geurts van Kessel A (1994)
   Comparative genomic hybridization as a tool to define two distinct chromosome 12-derived amplification units in well-differentiated liposarcomas
   Genes Chromosomes Cancer, 9 (4), 292-5
   DOI 10.1002/gcc.2870090410, PubMed 7519052

Publications 1993

1. ANDREASSEN A, BORRESEN AL, OYJORD T, SOLHEIM OP, FLORENES VA, BRULAND O, MYKLEBOST O, HOIE J, FODSTAD O (1993)
   CHROMOSOME-17P ABERRATIONS AND P53 EXPRESSION IN HUMAN SARCOMAS
   FRONTIERS OF OSTEOSARCOMA RESEARCH: INTERDISCIPLINARY SURVEY OF CLINICAL AND RESEARCH ADVANCES, 419-422
2. Andreassen A, Oyjord T, Hovig E, Holm R, Flørenes VA, Nesland JM, Myklebost O, Høie J, Bruland OS, Børresen AL (1993)
   p53 abnormalities in different subtypes of human sarcomas
   Cancer Res, 53 (3), 468-71
   PubMed 8425179
3. Brzozowska A, Fries R, Womack JE, Grimholt U, Myklebost O, Rogne S (1993)
   Isolation, sequencing, and expression analysis of a bovine apolipoprotein E (APOE) cDNA and chromosomal localization of the APOE locus
   Mamm Genome, 4 (1), 53-7
   DOI 10.1007/BF00364665, PubMed 8422503
4. Forus A, Flørenes VA, Maelandsmo GM, Meltzer PS, Fodstad O, Myklebost O (1993)
   Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2
   Cell Growth Differ, 4 (12), 1065-70
   PubMed 8117620

Publications 1992

1. Flørenes VA, Aamdal S, Myklebost O, Maelandsmo GM, Bruland OS, Fodstad O (1992)
   Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression
   Cancer Res, 52 (21), 6088-91
   PubMed 1356624
2. Forus A, Myklebost O (1992)
   A physical map of a 1.3-Mb region on the long arm of chromosome 12, spanning the GLI and LRP loci
   Genomics, 14 (1), 117-20
   DOI 10.1016/s0888-7543(05)80292-7, PubMed 1427818
3. Skrede B, Blomhoff R, Maelandsmo GM, Ose L, Myklebost O, Norum KR (1992)
   Uptake of chylomicron remnant retinyl esters in human leukocytes in vivo
   Eur J Clin Invest, 22 (4), 229-34
   DOI 10.1111/j.1365-2362.1992.tb01456.x, PubMed 1499639

Publications 1991

1. Rogne S, Myklebost O, Olving JH, Kyrkjebø HT, Jonassen R, Olaisen B, Gedde-Dahl T (1991)
   The human genes for complement components 6 (C6) and 9 (C9) are closely linked on chromosome 5
   J Med Genet, 28 (9), 587-90
   DOI 10.1136/jmg.28.9.587, PubMed 1683409

Publications 1990

1. Myklebost O, Rogne S, Hjermann I, Olaisen B, Prydz H (1990)
   Association analysis of lipid levels and apolipoprotein restriction fragment length polymorphisms
   Hum Genet, 86 (2), 209-14
   DOI 10.1007/BF00197707, PubMed 1979958
2. Rogne S, Mevåg B, Gedde-Dahl T, Myklebost O (1990)
   Multiple RFLPs of human complement component nine (C9) detected by TaqI
   Nucleic Acids Res, 18 (10), 3112
   DOI 10.1093/nar/18.10.3112-a, PubMed 1971940

Publications 1989

1. Nenseter MS, Myklebost O, Blomhoff R, Drevon CA, Nilsson A, Norum KR, Berg T (1989)
   Low-density-lipoprotein receptors in different rabbit liver cells
   Biochem J, 261 (2), 587-93
   DOI 10.1042/bj2610587, PubMed 2549976
2. Rogne S, Myklebost O, Høyheim B, Olaisen B, Gedde-Dahl T (1989)
   The genes for apolipoprotein all (APOA2) and the Duffy blood group (FY) are linked on chromosome 1 in man
   Genomics, 4 (2), 169-73
   DOI 10.1016/0888-7543(89)90296-6, PubMed 2500391
3. Rogne S, Myklebost O, Stanley K, Geurts van Kessel A (1989)
   The gene for human complement C9 is on chromosome 5
   Genomics, 5 (1), 149-52
   DOI 10.1016/0888-7543(89)90100-6, PubMed 2767685

Publications 1988

1. Herz J, Hamann U, Rogne S, Myklebost O, Gausepohl H, Stanley KK (1988)
   Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor
   EMBO J, 7 (13), 4119-27
   DOI 10.1002/j.1460-2075.1988.tb03306.x, PubMed 3266596

Publications 1987

1. Rogne S, Skretting G, Larsen F, Myklebost O, Mevåg B, Carlson LA, Holmquist L, Gjone E, Prydz H (1987)
   The isolation and characterisation of a cDNA clone for human lecithin:cholesterol acyl transferase and its use to analyse the genes in patients with LCAT deficiency and fish eye disease
   Biochem Biophys Res Commun, 148 (1), 161-9
   DOI 10.1016/0006-291x(87)91090-4, PubMed 2823801

Publications 1986

1. Myklebost O, Rogne S (1986)
   The gene for human apolipoprotein CI is located 4.3 kilobases away from the apolipoprotein E gene on chromosome 19
   Hum Genet, 73 (4), 286-9
   DOI 10.1007/BF00279087, PubMed 3017837
2. Rogne S, Myklebost O, Olaisen B, Gedde-Dahl T, Prydz H (1986)
   Confirmation of the close linkage between the loci for human apolipoproteins AI and AIV by the use of a cloned cDNA probe and two restriction site polymorphisms
   Hum Genet, 72 (1), 68-71
   DOI 10.1007/BF00278820, PubMed 3002953

Publications 1985

1. Rogne S, Rønning OW, Myklebost O, Seglen PO, Pettersen EO (1985)
   Cell cycle traverse and protein metabolism in human NHIK 3025 cells: the role of anchorage
   J Cell Physiol, 125 (3), 528-32
   DOI 10.1002/jcp.1041250324, PubMed 4066771
2. Shaw DJ, Meredith AL, Sarfarazi M, Huson SM, Brook JD, Myklebost O, Harper PS (1985)
   The apolipoprotein CII gene: subchromosomal localisation and linkage to the myotonic dystrophy locus
   Hum Genet, 70 (3), 271-3
   DOI 10.1007/BF00273455, PubMed 2991117

Publications 1984

1. Humphries SE, Williams L, Myklebost O, Stalenhoef AF, Demacker PN, Baggio G, Crepaldi G, Galton DJ, Williamson R (1984)
   Familial apolipoprotein CII deficiency: a preliminary analysis of the gene defect in two independent families
   Hum Genet, 67 (2), 151-5
   DOI 10.1007/BF00272990, PubMed 6547689
2. Myklebost O, Rogne S, Olaisen B, Gedde-Dahl T, Prydz H (1984)
   The locus for apolipoprotein CII is closely linked to the apolipoprotein E locus on chromosome 19 in man
   Hum Genet, 67 (3), 309-12
   DOI 10.1007/BF00291359, PubMed 6088388
3. Myklebost O, Williamson B, Markham AF, Myklebost SR, Rogers J, Woods DE, Humphries SE (1984)
   The isolation and characterization of cDNA clones for human apolipoprotein CII
   J Biol Chem, 259 (7), 4401-4
   PubMed 6546757

Publications 1983

1. Humphries SE, Jowett NI, Williams L, Rees A, Vella M, Kessling A, Myklebost O, Lydon A, Seed M, Galton DJ (1983)
   A DNA polymorphism adjacent to the human apolipoprotein CII gene
   Mol Biol Med, 1 (5), 463-71
   PubMed 6094958